1 / 13

Introduction and current status of viral load access

ADVANCING THE LABORATORY PROFESSION AND NETWORKS IN AFRICA. Introduction and current status of viral load access. Anafi Mataka ASLM. IAS 2019 Satellite Session, Mexico City, 22 July 2019. Momentum for VL scale-up. F ully implemented in 68% of LMIC and partially implemented in 20% of LMIC.

weston
Télécharger la présentation

Introduction and current status of viral load access

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ADVANCING THE LABORATORY PROFESSION AND NETWORKS IN AFRICA Introduction and current status of viral load access Anafi Mataka ASLM IAS 2019 Satellite Session, Mexico City, 22 July 2019

  2. Momentum for VL scale-up Fully implemented in 68% of LMIC and partially implemented in 20% of LMIC.

  3. Progress towards 90-90-90 53 % 62 % 79 % Key facts HIV – from http://www.who.int/mediacentre/factsheets/fs360/en/

  4. High viral suppression rates across countries

  5. Population-wide global progress 4.3 Million 7.4 Million 7.7 Million 79 % 62 % 53 % Key facts HIV – from http://www.who.int/mediacentre/factsheets/fs360/en/

  6. Need is estimated using projected ART patient numbers and testing guidelines. Where national guidelines are unknown, the WHO’s recommendations of 2 tests for new patients and 1 test for existing patients is used. Source: CHAI projections of 19 high-burden countries (81% of people on ART in LMICs), supplemented by linear extrapolations of “Rest of World” by Avenir Health.

  7. Most molecular labs are in major urban centres… Kenya Zimbabwe Uganda Malawi Note: this slide only reflects the PCR testing labs used for VL testing in the public sector. This excludes private PCR testing labs or those used for research purposes. Some circle represent multiple labs in the same city

  8. … and so are the largest ART facilities where patients seek care 48% [33% -66%] of all patients1are at facilities close to centralized labs and can transport samples within 24 hours Can be accessed using EDTA blood Require alternative strategy 1 Data based on facility level ART patient numbers from Kenya, Malawi, Uganda and Zimbabwe

  9. Treatment failure management 8.85% Not enough viral load results are being used clinically 6.89% 5.97%

  10. Innovations for scaling up VL Access are key Plasma viral load and alternative technologies pipeline: capabilities and market size Multi-disease diagnostics integration Alternative technologies performance and regulatory status Tools to support viral load implementation HIV molecular diagnostics toolkit

  11. Thank You Become and ASLM member!

More Related